Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients (RENAISSANCE): A Randomized, Placebo-controlled, Double Blinded, Multicenter Clinical Trial of Sotagliflozin Versus Placebo
University of British Columbia
Summary
This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.
Description
RENAISSANCE (Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients) is a pragmatic, prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sotagliflozin in adult kidney transplant recipients (KTRs). Scientific Background and Rationale Kidney transplant recipients remain at substantial risk of premature death, cardiovascular disease (CVD), heart failure (HF), and progressive loss of kidney transplant function. Cardiovascular complications are a leading cause of death among KTRs, w…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 18 years 2. ≥ 6 months post living or deceased donor kidney transplant 3. Estimated glomerular filtration rate (eGFR) ≥20 ml/min/1.73m2 by the CKD-EPI-creatinine 2021 formula within 28 days prior to randomization. 4. At increased risk for worsening allograft function or cardiovascular event as defined by one of the following groups: 1. Type 2 diabetes 2. Body mass index ≥ 30 kg/m2 3. History of post-kidney transplant hospitalization for congestive heart failure (regardless of ejection fraction) 4. eGFR \<30 ml/min/1.73m2 5. Albuminuria (UACR ≥ 11.3…
Interventions
- DrugSotagliflozin
Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.
- DrugPlacebo
Matching placebo will be administered for 3-4.5 years.
Locations (25)
- University of MinnesotaMinneapolis, Minnesota
- NewYork-Presbyterian / Weill Cornell Medical CenterNew York, New York
- UNC Medical CenterChapel Hill, North Carolina
- Royal Prince Alfred HospitalSydney, New South Wales
- Royal Adelaide HospitalAdelaide, South Australia
- University of AlbertaEdmonton, Alberta